<DOC>
	<DOCNO>NCT02087748</DOCNO>
	<brief_summary>The purpose study evaluate analgesic efficacy Topical Voltaren Gel ( diclofenac sodium gel ) 1 % apply QID compare Placebo Subjects Experiencing Delayed Onset Muscle Soreness .</brief_summary>
	<brief_title>An Investigator Initiated , Within-Subject , Proof Concept Study Assess Efficacy Safety Voltaren Gel Subjects With DOMS</brief_title>
	<detailed_description>The purpose randomize , double-blind , placebo control , within-subject study evaluate efficacy topical diclofenac sodium gel ( DSG ) 1 % reduce pain associate delayed onset muscle soreness ( DOMS ) . Following exercise , subject report significant DOMS receive topical DSG 1 % apply 1 leg placebo apply every 6 hour 48 hour .</detailed_description>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Patients provide write informed consent prior enrollment Male female 18 35 year age . Patients engage regular low extremity fitness activity 2 time per week ≥2 consecutive week past 6 month prior screen . Female patient eligible follow apply : Not pregnant ( subject child bear potential must negative beta human chorionic gonadotropin ( βhCG ) pregnancy test screening ) ; Not lactate ; Not plan become pregnant within duration study ; Patients willing capable understanding cooperating requirement study . Patients able understand communicate English . Randomization Patients report DOMS score ≥4 rest ( numerical rating scale 0 10 , 0 pain 10 bad pain imaginable ) secondary delay muscle soreness right leave leg . The DOMS score rest report leg must within 3 point . Patients must report categorical pain rating moderate severe leg scale none , mild , moderate , severe prior randomization . Have body mass index &gt; 32 kg/m2 History active suspect esophageal , gastric , pyloric channel , duodenal ulceration bleed within 30 day precede screening . Psychiatric disease include major depression , bipolar disorder , anxiety , medical condition , opinion Investigator , would interfere evaluation study drug efficacy safety History clinically significant cardiovascular , cerebrovascular , metabolic , pulmonary , neurological , hematological , autoimmune , psychiatric endocrine disorder , include individual Type I Type II diabetes , clinically significant medical condition , opinion Investigator , may preclude safe study participation . Have surgery schedule undergo surgery hip knee within 6 month prior screen and/or study participation . Have significant biomechanical abnormality low extremity would preclude study evaluation , : peripheral central neurological disease , significant back pain ; symptomatic osteoarthritis hip , know , foot , painful condition low extremity . Have type orthopedic and/or prosthetic device skin abnormality legs may interfere local tolerability . Currently take corticosteroid topical analgesic anti inflammatory treatment whose duration action may affect study evaluation . Malignancy last 5 year , exception nonmetastatic basal cell squamous cell carcinoma skin surgically cure , Stage 1 cancer carcinoma situ cure resection localize radiation least 5 year prior screen evidence recurrence . History allergy ( cutaneous systemic ) , hypersensitivity , asthma following : diclofenac , paracetamol , acetylsalicylic acid , salicylic acid , NSAID cyclooxygenase 2specific inhibitor ( COXIB ) know intolerance ( cutaneous systemic ) ingredient gel , isopropyl alcohol propylene glycol . History known narcotic , analgesic , alcohol abuse . Any cognitive impairment would , opinion Investigator , preclude study participation compliance study procedure ( e.g. , Alzheimer 's dementia ) . Previously receive investigational product within 30 day schedule dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>DOMS</keyword>
</DOC>